Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your suggestion of battlefield uses is great steve - post-operatively and pain and strain management - why not? I have suggested Olympic teams, equestrian teams - give a few hundred away - let 'em try it and publish the testimonials!
Can you imagine if the US armed forces are using it overseas for our men and women in uniform - but not in the USA mainland or Hawaii cause that's a big FDA no, no? And the DOD can't get ActiPatch and ALLAY at camps, air and naval bases here in the states?
How high in the air do you think DC would jump over that one - drug-free pain management of our armed forces, but just not at home? Shame on whoever and whtever is holding up FDA device approvals, not just for BIEL, but other firms too. Can't compete when DC ain't listening - and, incredibly, while the state of Maryland gives BIEL a financial grant to expand its' business?
Laughable!
Vigilance pays bigfoot - thanks
Malaysia is shown by World Bank as having a population in 2011 of 28,860,000 (rounded) - another country, another 30 million or so. Is the Malaysia announcement related to marketing progress by Gro-International? If it were, I suspect their name would also appear in the PR.
It has to be pricing or people - there is just no way any smart retailer plays 'wait and see' today. Are you kidding? The drug store wars continue and retailers globally have to fight for every dollar. Either the marketing is ineffective, or the pricing is off. BIEL made a major shift in pricing a couple of years ago, does it need another look? Is this a combination of Founder's Syndrome plus pricing plus marketing people and not being on the NASDAQ OTC:BB? The answer is to be found in one or more or all of these areas IMO. And, if I'm anywhere close to being right, then the source of the issues is management or money, or both. I understand this company has survived so far on a shoestring, but 'Founder's Syndrome' if it is a part of this dilemma is often hard to deal with, but I have thrown this balloon into the air a few times, often enough for the CEO to be taking a long and introspective look at things. Often, the "Founder's Syndrome' solution is to kick the CEO upstairs, to Chair only, and get a hotshot CEO on board with a good piece of the upside. Results count!
With the patented product line, including ALLAY which could help tens of millions of women with severe menstrual pains, no negative side-effects, ever, and all the "BIEL facts" I posted again recently, on products, the understaffing at the USFDA, etc., etc., I agree with fellow-poster, this should be 20 cents or north of it. I remain confused.
Great grinding, every bit of information helps the picture - thanks wyatt
Kid - just fell out of my chair - after all you have contributed, you're not back in? Tell me your kidnova-ing me, please.
Just controlling the run?
Hahahaha Myachinbak
Ya got me - that's my ask at 25 cents, figured I would blow some out in the morning as the price blows by on the way up - I was holding out for half a buck as my exit strategy, but feel it is prudent to take some profits at a quarter. Is my ask too low? If so, please advise. Thanks very much
hey steelyeye - was that email address yahoo.com?
I have it as 229,949,450 from Valentine's Day when the BIEL / Gro-International deal for the EU and Africa was announced to and including March 7
Then, from March 8 to and including today
3,660,800
2,838,600
1,846,000
3,327,627
3,387,489
9,070,926
23,641,124
12,282,140
9,807,760
13,089,572
35,970,116
51,026,082
399,897,686 total. 400 million – I may have messed up for one long travel day Hong Kong, but I’m close. You can probably verify the accuracy somewhere in a nanosecond. Bottom line, a lot of shares
Cheers
et tu comprendre le petit morceau concernement les mots sur notre ami griffoner?
et le petit oiseau - il dit quand lorsqu'il s'agit de s'il te plait?
we now know - yes, sure, it requires those who have patience, the rest is going to become, it is only a question (meaning matter of) of time.
I've asked - if I understand you about the piece and the words concerning our friend - and does the little birdie - does he say when it is to be, please?
Hey mad - comprendre-tu le message dernier a tu?
Very informative and thought provoking - thanks Stock for sharing your experience
Ha mad garcon - merci beaucoup - je comprendre en total - le grand avenir apres beaucoup des problems, non? Parce ce que pour ddl, va ta faire et tu comprendre etc pour ddl, oui? Ci M. Whelan et associates faire un bon management immediatement, c'est tres, tres, important, non bientot, immediatement!!!!!! a bientot mad merci
To translate for the rest of the good guys - we have a good future; this is only the first step of a large or great future.
I responded, "thanks very much,it will be a I understand totally, it will be a grand future after many problems, no? If Mr. Whelan and associates make (or build) a good management immediately, it is very, very important, not soon, immediately, today, this instant. see you soon mad, thanks
Thank you rusty college French, I have a headache.
Embarassing BabyFresh
Health Canada approved for OTC
UK as well
Spain and a host of other developed countries too
I recall BIEL making a deal with China, help me here, was it research? Trials? Approved? Can't recall at the moment.....
And here we are stateside - state of Maryland tapayers grant funds to BIEL to develop its business overseas and our regulatory authorities snail pace OTC approval here, not just for BIEL, but a number of firms applying for device approval because the space is so new, there are no experts to approve it. See my post at 28907 - shameful. It would seem to me to be a perfect opportunity for the FDA and DC to both save face by granting approvals to a number of American companies being held up by red tape - no drugs, no side-effects ever! Stop the nonsense.
Just catching up - on the road for a couple of hours
Agree this is not just April 5 FDA meeting or Spanish docs show or shorts.
Remember the spot on the Dr. Oz show yielded great sales short term but didn't do much to SP.
I smell a potential combination of many things.
Madp, I respect your need to be hesitant in a delicate situatuion, but are you able to check the birdcage quietly and see if the birdie has an update as to how much of the 'good things' are out and how much is left? And then somehow let us know cryptically? Up to you of course, wouldn't want you to blow such an amazing intel source, but you have been bang-on so far.
Thanks mad
Here is your post 28464 mad, less than a month ago and 2 weeks after the announcement of the Gro-International deal for the EU and Africa:
"no...little birdie said much more to come...."
Given your blank post just now, I'm sorry, but I just can't resist.......
Bird got your tongue?
Without humor, what are we? We are nothing.
Cheers mad
Gosh......wouldn't it be a great thing if the management of BIEL would shift the company to the NASDAQ OTC:BB? I have nothing against any market place - just that I have read here it would be good and I know from my own broker that their exposure to 10's of millions of potential US investors and a large uplift in credibility with brokers would be a good thing. What is the cost? The company raised a lot of survival money in the past couple of years, be nice if that had been done, oh well. C'mon Mary, kick your brother in the BIEL and tell him to do it! There will never be a better time IMO.
Hey ddls - your post "According to my calculations, this is it. .004! "Topos""
I'm confused - it is now sitting %5 higher than that at .0042 with 30.5 million in volume at just after 3pm and up 40% on the day, whereas you said it was BK at .0014. Not offering anything up but that you have confused me. But then, I guess I can't calculate and Steve can't spell, sure wish you could help. Maybe Imrich had it right when he suggested 20 cents by summer, just out by an FDA year. Thanks
Hey Casper - to you, gman and finish
Look at madp's posts
Madp 28470
my post 28482
Then madp's 28483
It may be foolish for madp to inappropriately reveal the source or birdie and specifically what the source said as that might reveal the 'whom'.
I'm comfortable that madp heard something from a possibly very reliable source and don't need to know more when I see what I'm seeing in recent days.
In 2009 I watched BIEL run to 12 cents plus on hype of a snap FDA approval - this time it 'seems' to be different and based on totlly different intel and also affecting numerous other firms also seeking regulatory device approvals from the FDA, which heretofore the FDA apparently said they were unable to assess because of the newness of the electronic device space.
My money says every one of the good guys is here - all got tired of firstly the frustration with BIEL management and zero traction and forward movement, along with the incessant bashers with personal grudges. Guess I just stated your "years of bantering and doldrums" comment another way, you were right on! Part of the process that gets really tiring really quickly, like calling steve on his spelling? What? All good, if BIEL is now starting to perform as it should.
Hey finish - I'm jammed for time but here is a combination of a few posts to help bring you up to speed from my perspective - not pumping, I'm a share holder, but you asked and I'm trying to help you by responding.
March 23 #28885
Hey Steve - I disagree - I don't see it as pumping to state facts and you have furnished us with many, along with your opinions based on those. Pumping? No. What has always bothered me is the 'dumping' in conflict with the reality of BIEL. Yes, there are management issues that need addressing, but the company will not be selling Whelans, and the FDA is not assessing approvals of Whelans - BIEL involves ActiPatch, ALLAY, RecoveryRx and many others in the product line.
I posted to you the following message on January 17 based on what I understood to be the facts at that moment in time. A lot has happened since then including a doubling in SP. If BIEL and its BOD can get help on the management horsepower side and the FDA approvals I think it deserves, along with other companies in the PEMF device space, my opinion is this puppy will fly. Is that pumping? Or, closer to reality than simply pounding something for the sake of pounding it.
SENT EARLIER January 17 to Steve43
Hey Steve - when you mention all the countries that have issued OTC regulatory approval for BIEL's product line, like Health Canada and in the UK, please don't forget the FDA here at home. The FDA has approved BIEL's 'RecoveryRx' product as a healing accelerator device for post-op opthalmic surgery patients, when prescribed, with remarkable results. Imagine that!
But, now, I choose to completely ignore the almost OCD naysayers and stick solely with the facts of BIEL products.
Fact - ActiPatch really works well - I know first-hand because I used it on a serious injury and my doctor could not believe the results;
Fact - it is financially affordable;
Fact - it is not a drug, no chemicals rampant with side-effects;
Fact - there has never been one, not one, negative side-effect, imagine a BIEL TV slot - "sorry no negative side-effects";
Fact - we, along with BIEL management, must be patient, success takes time;
Fact - BIEL's management could have done several things differently, but we don't know anything about the decisions they faced and why, so we should have no comment now about the past;
Fact - the FDA didn't get it right first time either, it's new, and the FDA is now re-assessing all PEMF devices;
Fact - many very, very bright, articulate scientists have put their knowledge and wisdom forward in support of BIEL and other firms; and
Fact - I have said all this before, as have many posters here, and not one naysayer has refuted one word of the facts.
THEN March 23 #28887
OK Steve - in the last couple of hours, diarch asked in a post what BIEL might be worth in a best-case scenario and asked if perhaps 2 bits might be a realistic number.
yankee55 asked about thoughts/reasons for the recent upside move.
My last post set out some, not all current goings on like - the Gro-International deal Feb 14 for the EU and Africa, London England Gala BIEL received runner up device award to the Boots no-touch thermometer, the recent publicity at Johns Hopkins gala and it was just that - good publicity bought or not, the upcoming public meeting hosted by the USFDA in a couple of weeks on April 5th and the fact that the FDA apparently admitted they did not have the scientific horsepower in-house to assess electronic devices and were going to hire 200 people (I liked the honesty of that, if true!)....
Then you opined in your last post about 20 cents, without FDA approval.
Would you please share your thoughts if BIEL does get OTC approval for its devices? Remembering that so much of the regulatory approval process is avoiding getting a permanent 'no'.
In other words, "we ain't dead yet". And if your opinion is 1 cent, 3 cents, or $3.00 WITH FDA approval, in other words, the best-case scenario diarch asked for, please be frank.
You may wish to couch your opinion with a 2-stage scenario. For instance, the public meeting doesn’t produce a yes or a no for the numerous companies applying for OTC approval for their devices, but the FDA takes everything under advisement which, in essence, means we ain’t dead yet and the company lives to fight another day in the painful approval process. Ughhh.....
Give it your best shot steve - thanks
THEN March 23 #28888
Oooops, almost forgot these two facts!
Alex Gorsky was recently appointed, let's see, Chairman BOD, CEO, Chairman of the Executive Committee of J&J. His previous assignment was Director of the J&J devices division. I just looked at the list and mini-bios of J&J's 13 directors - do you think just one of those trememndously accomplished people might just ask the question, "should we increase our presence in the pain treatment device space?"
Then the other fact is that Gregor Forbes, heading up Gro-International, while he doesn't have the guns of Alex Gorsky, does have 28 years in the OTC pharma space, 25 of them with P&G.
None of this is to say anything is in the wind or I'm pumping anything, I just find it interesting and nothing would suprise me given that BIEL products are drug free, treat pain and promote healing of compromised tissue. The FDA has already approved that RecoveryRX is safe when prescribed to post-op patients having opthalmic surgery. That would be the eye area, close to the brain!
And if I'm Whelan at BIEL, I'm talking to both J&J and P&G to at least keep the lines of communication open. I see Whelan as a stubborn, somewhat aging ex-US Marine, who for a time probably wanted to go it alone, Founder's Syndrome, but even those types have to eat and Whelan could eat very, very well, as I see it.
Cheers finish - hope this helps
I don't mind Mary's involvement at all, as if I have any say. In fact, she appears to be very effective, knows her stuff and has a congenial style.I just don't like 'exclusive' representation deals. If Mary is the one, she will perform - if she is great, she will outperform all others. Exclusivity is controlling and leaves the door open for laziness and mediocrity without accountability, like limits, "this just isn't working, we have to go in another direction, bye bye".
Only thing better than a good distributor of one's products is two good distributors. Particularly, when they don't put skin in the game and carry large inventories, as may be the case here.
Hah, don't want to appear to be a pumper Casper - just the facts man....
Not unreasonable views at all Steve and, for the record, you're no pumper, you're a valuable contributor here, so ignore the bashers on that and your spelling :).
I've seen a number of executives who have suffered from 'Founder's Syndrome' until they either failed, or until someone close kicked them in the -$$ long and hard until they realized they were completely missing the gravy boat because of it. Only then did they reluctantly get out of their own way, claiming like many reformed sinners, booze, drugs, etc., that stepping aside was their idea alone. Agonizing and amazing to watch, particularly for investors in private firms and public company shareholders like us.
As I've said before, if anyone thinks for a second that Whelan doesn't know what his shareholders think, I have a bridge for sale at a modest price, first come first served and-attractive terms. He knows. I nominate Steve as CEO of BIEL! First task? Kill the HealFast deal.
Thanks very much for your well thought out feedback ts, like your concise approach and math. Between you and Steve - the range is 20 to 74 cents. I think I'm a seller at half a buck.
Oooops, almost forgot these two facts!
Alex Gorsky was recently appointed, let's see, Chairman BOD, CEO, Chairman of the Executive Committee of J&J. His previous assignment was Director of the J&J devices division. I just looked at the list and mini-bios of J&J's 13 directors - do you think just one of those tremendously accomplished people might just ask the question, "should we increase our presence in the pain treatment device space?"
Then the other fact is that Gregor Forbes, heading up Gro-International, while he doesn't have the guns of Alex Gorsky, does have 28 years in the OTC pharma space, 25 of them with P&G.
None of this is to say anything is in the wind or I'm pumping anything, I just find it interesting and nothing would suprise me given that BIEL products are drug free, treat pain and promote healing of compromised tissue. The FDA has already approved that RecoveryRX is safe when prescribed to post-op patients having opthalmic surgery. That would be the eye area, close to the brain!
And if I'm Whelan at BIEL, I'm talking to both J&J and P&G to at least keep the lines of communication open. I see Whelan as a stubborn, somewhat aging ex-US Marine, who for a time probably wanted to go it alone, Founder's Syndrome, but even those types have to eat and Whelan could eat very, very well, as I see it.
OK Steve - in the last couple of hours, diarch asked in a post what BIEL might be worth in a best-case scenario and asked if perhaps 2 bits might be a realistic number.
yankee55 asked about thoughts/reasons for the recent upside move.
My last post set out some, not all current goings on like - the Gro-International deal Feb 14 for the EU and Africa, London England Gala BIEL received runner up device award to the Boots no-touch thermometer, the recent publicity at Johns Hopkins gala and it was just that - good publicity bought or not, the upcoming public meeting hosted by the USFDA in a couple of weeks on April 5th and the fact that the FDA apparently admitted they did not have the scientific horsepower in-house to assess electronic devices and were going to hire 200 people (I liked the honesty of that, if true!)....
Then you opined in your last post about 20 cents, without FDA approval.
Would you please share your thoughts if BIEL does get OTC approval for its devices? Remembering that so much of the regulatory approval process is avoiding getting a permanent 'no'.
In other words, "we ain't dead yet". And if your opinion is 1 cent, 3 cents, or $3.00 WITH FDA approval, in other words, the best-case scenario diarch asked for, please be frank.
You may wish to couch your opinion with a 2-stage scenario. For instance, the public meeting doesn’t produce a yes or a no for the numerous companies applying for OTC approval for their devices, but the FDA takes everything under advisement which, in essence, means we ain’t dead yet and the company lives to fight another day in the painful approval process. Ughhh.....
Give it your best shot steve - thanks
Hey Steve - I disagree - I don't see it as pumping to state facts and you have furnished us with many, along with your opinions based on those. Pumping? No. What has always bothered me is the 'dumping' in conflict with the reality of BIEL. Yes, there are management issues that need addressing, but the company will not be selling Whelans, and the FDA is not assessing approvals of Whelans - BIEL involves ActiPatch, ALLAY, RecoveryRx and many others in the product line.
I posted to you the following message on January 17 based on what I understood to be the facts at that moment in time. A lot has happened since then including a doubling in SP. If BIEL and its BOD can get help on the management horsepower side and the FDA approvals I think it deserves, along with other companies in the PEMF device space, my opinion is this puppy will fly. Is that pumping? Or, closer to reality than simply pounding something for the sake of pounding it.
January 17 to Steve43
Hey Steve - when you mention all the countries that have issued OTC regulatory approval for BIEL's product line, like Health Canada and in the UK, please don't forget the FDA here at home. The FDA has approved BIEL's 'RecoveryRx' product as a healing accelerator device for post-op opthalmic surgery patients, when prescribed, with remarkable results. Imagine that!
But, now, I choose to completely ignore the almost OCD naysayers and stick solely with the facts of BIEL products.
Fact - ActiPatch really works well - I know first-hand because I used it on a serious injury and my doctor could not believe the results;
Fact - it is financially affordable;
Fact - it is not a drug no chemicals rampant with side-effects;
Fact - there has never been one, not one, negative side-effect, imagine a BIEL TV slot - "sorry no negative side-effects";
Fact - we, along with BIEL management, must be patient, success takes time;
Fact - BIEL's management could have done several things differently, but we don't know anything about the decisions they faced and why, so we should have no comment now about the past;
Fact - the FDA didn't get it right first time either, it's new, and the FDA is now re-assessing all PEMF devices;
Fact - many very, very bright, articulate scientists have put their knowledge and wisdom forward in support of BIEL and other firms; and
Fact - I have said all this before, as have many posters here, and not one naysayer has refuted one word of the facts.
My error hooker and kid - the www.Biomax.it part of the PR says that their alignment with Medical Distribution Srl and OneGlobe Biotech "to expand our 50+ sales representatives to serve all Italian pharmacy and hospital supply chains." Firstly I have no idea how many reps the other two have, one looks like a pure research org from its website but you would think the PR would be more revealing, is it 60, 70, 80 reps, 100 reps, combined?
Secondly, the Biomax sales force screams OTC if they are going to pitch all Italian pharmacies......sorry I missed that. Hopefully this crew does a much better job than than the last group you referenced kid.
Like your take on Italy hooker - 50 sales reps seems like a formidable sales force to penetrate the Doctor's offices. Hospital reps pitching the surgical staffs repeatedly should be significant, as that's where RecoveryRx begins. They should be all over the in-house pharmacy staff members.
You mention only RecoveryRx - why not ActiPatch and ALLAY in Italy as well? Are they not approved there yet? Thank you for any info.
Totally agree gman - too much volume and sp increase to be just another distributorship or two, even though Italy has good population numbers. IMO it's related to either FDA anticipation, someone or a group here stateside knows something about that we don't, or perhaps related to Gro-International efforts or news in the EU, etc. It's 5 weeks since the Gro-International deal was announced, was Italy a result of their efforts? Who knows, but it's not negative to have a 60 odd million market added to the BIEL stable of countries. Just need to generate sales now.
No kidding Casper - remember when it ran to 12 1/2 cents? Was that not 2009, and based solely on rumor because the company had applied to the FDA for approval? You're right, by buying at the ask, the stock is bought, deal's done and who cares about .0001 or so, if it is going to run in anticipation of the FDA meeting April 5th?
Because some smart money or corporation now 'gets it' that BIEL is going to the FDA public meeting April 5th on applications and regulatory approvals in the PEMF device space, which the FDA may not have had the internal staff to assess in the past.
I see that 252 million shares have traded since the company did a marketing deal for the EU and Africa, may countries on the Med announced Feb 14. The products work, they are drug free and no negative side-effects - that's it. Read back 25 posts and you'll see more. I'm a shareholder and therefor conflicted, but I've used the products and they work amazingly well.
BIEL is such a no-brainier. ActiPatch and ALLAY, the main players.
Who in government or the FDA today would or could not see the advantages?
Women by the millions relieved of serious menstrual cramping costing the economy billions of dollars every year with ALLAY and a pain relieving, drug-free solution for minor injuries with ActiPatch? That's drug-free, with no negative side-effects, ever? It is total nonsense that BIEL's product line is not already approved for OTC sales, but the FDA apparently stated that it was hiring 200 people to deal with the emerging device market and related applications for regulatory approval. I have to say I did not see a press release to this effect myself, read about it here. I'm sure one of the other shareholders knows how to access that announcement. Many shareholders who know first-hand how well the products work are enraged at the time-wasting delays in the device product space. BIEL is not the only company disadvantaged by the government supposed to help expedite their growth!
What has made things more embarrassing is that the state of Maryland gave the company a grant to advance its business overseas and it has with OTC regulatory approval from Health Canada and in the UK! Are we crazy? No, just late! Hopefully the public meeting with the FDA in April will allow this little company to become a winner. No one else can bring the products to market - they're patented! Between the government and the FDA, we can't get out of our own way and the American people lose again. Maybe the FDA can save face by blaming DC......
I agree wholeheartedly - how big a holder are you?
I wrote a few posts ago that I knew you to be a bright person. Thank you for confirming how bright.
Cheers
Hahahaha way ta go kid
Next year I want the award for Individual Dinner Ticket person because I will blow 180 bucks on a ticket. I doubtWhelan got the award because he ponied up $50K. He's too cheap! Regardless,he received the award for delivering an innovative product to marker - did I read that? Has BIEL not been jerked around by the FHA? Have I not read that too?
Thank you for reviewing your thoughts and comments with such fairness fuente.
I now feel confident I am encumbered with the truth and an appropriate sense of fair play. I take such things as besmirching another's reputaton and dignity quite seriously, not laughably. Thanks again.
Cheers
You are right veto.
Fuente, I've read every one of your posts since I bought $25K of shares in BIEL January 2012. That was not the first or the last. I know you to be a bright person, but on this one, you missed it. Whelan did not win "humanitarian of the year" as you suggest. What he won on behalf of BIEL and its' products is far, far better. For the American people, as potential users of BIEL products, and for you and me. Read it again, I will say no more.
Cheers
hey shado - good question - why do I think the FDA cares?
Because to go through the growing pains the FDA has in having to catch up to the blossoming devices space by saying they are going to hire 200 people is one thing. OK, they got caught by new technology. I get that part.
To take a few years to realize there are not enough people scientifically skilled to assess PMF and other new products in the devices space is a little embarrassing, that's another, I get that too.
But to have BIEL win runner-up for the innovative new product of the year in the UK AND the award Whelan won at The Johns Hopkins award dinner in Baltimore both in the same week, with the State Of Maryland taxpayers having funded BIEL's activities overseas with a grant is now humiliating. I don't have the info to be able to say this to the good lady Senator for Maryland, Ghost can you help? This shado is why the FDA will now care. Numerous respected countries approve BIEL for OTC, including the UK and Canada, the two best allies our country has ever had, both with rigorous health regulatory processes? And BIEl approved for OTC? What?
I have been critical of Andrew Whelan at the inactivity in marketing and sales of BIEL's products, for which I am sorry, if I was wrong. My opinion is now changing to placing more responsibility directly on the FDA and its masters in Washington. That is not to say Whelan could not have done more, but I cut him some slack for three reasons. He's an ex-Marine and earned my respect for that - he has seemingly run BIEL on a shoestring and I am confident our company, yes, our company because I'm a shareholder, has been jerked around by the FDA being behind in the management of regulatory affairs in the device space. Seems to me this award from Johns Hopkins, one of the most prestigious bodies in the world, cannot be friends looking after friends in the State of Maryland, Johns Hopkins is above that, too much to lose in global reputation. And it ain't political for the same reasons.
I don't want to be the fDA Director taking a call from the Senator this afternoon, "Good afternoon Director, this is Senator McKluskey, thank you for taking my call, I was just wondering about a couple of things, how preparations are going for you to answer the questions which will be asked as to why BioElectronics, a corporation located in my state won runner-up for innovative medical device product of the year at a gala dinner in London, England and its CEO won an incredible award from Johns Hopkins, both in the same week and my follow-up question is where might you be planning to be working come April 1st?
To say the BIEL debacle is outrageous is minimizing it. It is now humiliating to the FDA, Washington and our country. Bottom line? Remember, I've used ActiPatch, it works, no negative side-effects, ever! When will the absurdity end? When the FDA cares because that will be when it is time to approve a line of products that help people with pain relief and healing, when their jobs and credibility are really on the line, which would be about right now, and, oh, I almost forgot, they are all DRUG FREE. And we're gonna re-name the FDA the FHA. Food and Health Administration, sort of like Health Canada, eh? How embarrassing!
Sorry Steve - leave a voice message - cause I'm on the road - I'm on my way to a meeting with the Leone family in New Jersey - ex president and CFO in that equestrian family of the US Equestrian Federation. Gonna pitch them on HealFast or whatever for the nags and ActiPatch for the riders for the US Equestrian Team and some advertising for the next Olympics -----now isn't that a dumb idea that might just hit a home run or a Triple Crown?
And would I take my little van around to every major stable in Kentucky with the best pain reliever since Bute, which is now illegal and will get a user banned for life? And the tracks and stables and horse farms in Maryland? Home of BIEL. Go Mrs. Whelan! Make a few million!